Program
bulevirtide
Also written as “Bulevirtide” and “Bulevirtide (BLV)”.
Its studies are mostly in Hepatitis D, Chronic, led by 2 companies.
Furthest: phase 3, since Feb 21, 20195 company-led studies, 1 open or runningNext primary completion: Aug 31, 2027 (phase 3)
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Gilead Sciences | 40 open or running | phase 3since Feb 21, 2019 | Feb 21, 2019 | none ahead |
| Mirum Pharmaceuticals | 11 open or running | phase 3since Mar 2, 2026 | Mar 2, 2026 | Aug 31, 2027phase 3 · NCT07454837 |
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Feb 21, 2019First study: phase 3 study in Hepatitis D, ChronicNew to Gilead SciencesGilead Sciences · NCT03852719 · 150 enrolled · United States, Germany, Italy and more
- Feb 21, 2019Phase 2 study in Hepatitis D, ChronicGilead Sciences · NCT03852433 · 175 enrolled · France, Moldova, Republic of, Romania and more
- Feb 27, 2023Phase 1 study in Chronic Hepatitis D InfectionGilead Sciences · NCT05760300 · 41 enrolled · United States
- Mar 1, 2023Phase 1 study in Hepatic ImpairmentGilead Sciences · NCT05765344 · 74 enrolled · United States
- Mar 2, 2026Mirum Pharmaceuticals's first study: phase 3 study in Hepatitis D, ChronicNew to Mirum PharmaceuticalsMirum Pharmaceuticals · NCT07454837 · 120 planned · Austria, Czechia, France and more
Ahead
- Aug 31, 2027Primary completion: phase 3 study in Hepatitis D, ChronicMirum Pharmaceuticals · NCT07454837
TargetBeta
SLC10A1 →read by rule
“Bile acid transporter inhibitor”ChEMBL 37, by rule
Other programs on SLC10A1
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| hepalatiderule | shanghai-hep-pharmaceutical-co-ltd | phase 3 | 8 |
Studies
All 5 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT07454837Hepatitis D, Chronic · Austria, Czechia, France and more | 3 | Recruiting | Mirum Pharmaceuticals | Aug 31, 2027 | 120 |
| NCT05765344Hepatic Impairment · United States | 1 | Completed | Gilead Sciences | Jan 10, 2025 | 74 |
| NCT05760300Chronic Hepatitis D Infection · United States | 1 | Completed | Gilead Sciences | Jul 18, 2024 | 41 |
| NCT03852719Hepatitis D, Chronic · United States, Germany, Italy and more | 3 | Completed | Gilead Sciences | Nov 26, 2020 | 150 |
| NCT03852433Hepatitis D, Chronic · France, Moldova, Republic of, Romania and more | 2 | Completed | Gilead Sciences | Apr 5, 2022 | 175 |
How it is read
Names in the registry
- “Bulevirtide”, 5 entries
- “Bulevirtide (BLV)”, 1 entry
Conditions, from the studies’ own filings
- Hepatitis D, Chronic, 4 studies
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.